Powder: -20°C for 3 years | In solvent: -80°C for 1 year
R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
ターゲット&IC50 | VEGFR2:24 nM, Axl:136 nM |
In vivo | Treatment with R916562 at dosages of 85 mg/kg or 125 mg/kg (administered orally twice daily for 21 days) leads to statistically significant tumor growth inhibitions of 69% and 83%, respectively. Additionally, R916562 achieves a 73% reduction in fibroblast growth factor-induced neovascularization in the mouse corneal micropocket assay at 100 mg/kg, and a 50% reduction at 50 mg/kg[1]. |
分子量 | 536.09 |
分子式 | C26H30ClN9S |
CAS No. | 1037798-41-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
R916562 1037798-41-6 Tyrosine Kinase/Adaptors TAM Receptor R 916562 R-916562 Inhibitor inhibitor inhibit